HBK Sorce Advisory LLC Has $461,000 Stake in GlaxoSmithKline plc (GSK)

HBK Sorce Advisory LLC raised its stake in GlaxoSmithKline plc (NYSE:GSK) by 30.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,645 shares of the pharmaceutical company’s stock after purchasing an additional 2,952 shares during the quarter. HBK Sorce Advisory LLC’s holdings in GlaxoSmithKline were worth $461,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. FMR LLC increased its position in shares of GlaxoSmithKline by 1.7% during the third quarter. FMR LLC now owns 19,081,274 shares of the pharmaceutical company’s stock valued at $766,495,000 after acquiring an additional 327,721 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of GlaxoSmithKline by 1.4% during the third quarter. Fisher Asset Management LLC now owns 14,011,328 shares of the pharmaceutical company’s stock valued at $562,835,000 after acquiring an additional 187,205 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of GlaxoSmithKline by 8.6% during the third quarter. Renaissance Technologies LLC now owns 10,135,200 shares of the pharmaceutical company’s stock valued at $407,131,000 after acquiring an additional 805,800 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of GlaxoSmithKline by 1.7% during the second quarter. Federated Investors Inc. PA now owns 4,366,175 shares of the pharmaceutical company’s stock valued at $176,000,000 after acquiring an additional 73,981 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of GlaxoSmithKline by 19.6% during the second quarter. Morgan Stanley now owns 3,615,525 shares of the pharmaceutical company’s stock valued at $145,742,000 after acquiring an additional 592,022 shares during the last quarter. 10.97% of the stock is owned by hedge funds and other institutional investors.

NYSE:GSK opened at $37.61 on Friday. The company has a debt-to-equity ratio of 6.66, a current ratio of 0.95 and a quick ratio of 0.63. GlaxoSmithKline plc has a 1 year low of $34.83 and a 1 year high of $42.36. The firm has a market capitalization of $93.27 billion, a price-to-earnings ratio of 12.54, a PEG ratio of 2.54 and a beta of 0.81.



GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, October 31st. The pharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.03). GlaxoSmithKline had a return on equity of 164.99% and a net margin of 5.78%. The firm had revenue of $9.41 billion during the quarter, compared to analysts’ expectations of $10.55 billion. On average, equities research analysts predict that GlaxoSmithKline plc will post 2.95 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 10th. Shareholders of record on Friday, November 16th will be given a $0.486 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.46. This represents a $1.94 dividend on an annualized basis and a yield of 5.17%. The ex-dividend date is Thursday, November 15th. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 67.36%.

GSK has been the subject of a number of research analyst reports. SunTrust Banks initiated coverage on GlaxoSmithKline in a research report on Thursday. They set a “hold” rating and a $38.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price target on shares of GlaxoSmithKline in a research report on Tuesday, December 11th. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Wednesday, November 28th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, September 25th. Finally, Wolfe Research started coverage on GlaxoSmithKline in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $41.71.

ILLEGAL ACTIVITY WARNING: “HBK Sorce Advisory LLC Has $461,000 Stake in GlaxoSmithKline plc (GSK)” was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://dakotafinancialnews.com/2018/12/16/hbk-sorce-advisory-llc-has-461000-stake-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Inflation

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply